Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI boosts doctor accuracy for rare skin diseases in new study

NCT ID NCT07428915

Knowledge-focused Sponsor: AI Labs Group S.L Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first gave their diagnosis without AI help, then saw the AI's suggestions and could change their answer. The goal was to see if the AI improved diagnostic accuracy, especially for rare diseases that are often missed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

15 people

The number who actually took part.

Started

Jun 2024

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of board-certified healthcare professionals recruited from the clinical fields of general medicine and dermatology. The participant group includes: * Primary Care Practitioners: General practitioners who often serve as the first point of contact for patients with dermatological symptoms. * Specialist Dermatologists: Physicians with advanced expertise in skin pathologies and rare conditions. * Experience Level: The cohort includes practitioners with at least 5 years of clinical experience in their respective specialities. Participants were recruited to engage in a remote, web-based evaluation environment rather than being selected from a single physical hospital or town. The clinical images evaluated as part of the study "cases" were sourced from international public dermatology atlases and existing research databases from the sponsor, representing a diverse global patient population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified general practitioners and dermatologists, regardless of their professional experience. * Good quality images of patients with GPP. * Good quality images of patients with HS. * Good quality images of patients with pathologies that can be confused with GPP or HS, leading to a wrong diagnosis. Exclusion Criteria: * Images of patients with pathologies different from GPP or HS that can be easily identified.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Conglobata Acne Vulgaris acute generalized exanthematous pustulosis atopic eczema generalized pustular psoriasis hidradenitis suppurativa impetigo palmoplantar pustulosis pemphigus pemphigus vulgaris psoriasis pustular psoriasis Rare Diseases seborrheic dermatitis seborrheic keratosis skin disorder Tinea tinea corporis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne Acne conglobata Acute generalized exanthematous pustulosis Eczema atopic dermatitis Generalized pustular psoriasis (GPP) Hidradenitis suppurativa (HS) Impetigo Palmoplantar pustulosis Pemphigus vulgaris (PV) Plaque psoriasis Pustular psoriasis (PP) Seborrheic dermatitis Seborrheic keratoses Tinea corporis

Contacts and locations

Locations

  • AI Labs Group S.L.

    Bilbao, Basque Country, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.